Lunesta Sepracor Inc. - Treatment for Insomnia
Lunesta is a nonbenzodiazepine hypnotic agent indicated for the treatment of patients who experience difficulty falling asleep as well as for the treatment of patients who are unable to sleep through the night (sleep maintenance difficulty).Posted: December 2004
Related articles
- Sepracor Announces FDA Acceptance of Estorra NDA Resubmission and Issuance of Class 2 Review Designation - July 15, 2004
- Sepracor Announces Resubmission of Estorra NDA to FDA - June 16, 2004
- Sepracor Announces Approvable Action for Estorra (eszopiclone) for the Treatment of Insomnia and Provides Update on Launch Plans - March 1, 2004
Lunesta (eszopiclone) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
